Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple switches between Humira and ABP 501 vs continued Humira in moderate to severe plaque psoriasis
2021-000542-18Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in plaque psoriasis (2 arms), sponsored by Amgen. Primary endpoint: Pharmacokinetic parameters after multiple switches vs continued adalimumab. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2021-000542-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000542-18.